Last reviewed · How we verify
Commercial naproxen sodium tablet
Naproxen sodium inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
Naproxen sodium inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever. Used for Mild to moderate pain, Fever, Inflammation associated with conditions such as headache, muscular aches, backache, minor arthritis pain, menstrual cramps, and the common cold.
At a glance
| Generic name | Commercial naproxen sodium tablet |
|---|---|
| Also known as | Commercial NPX tablet |
| Sponsor | Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | COX-1, COX-2 |
| Modality | Small molecule |
| Therapeutic area | Pain Management, Inflammation |
| Phase | Phase 3 |
Mechanism of action
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively blocks COX-1 and COX-2 enzymes. By inhibiting prostaglandin production, it reduces inflammatory mediators and pain signals. The sodium salt formulation allows faster absorption and onset of action compared to base naproxen.
Approved indications
- Mild to moderate pain
- Fever
- Inflammation associated with conditions such as headache, muscular aches, backache, minor arthritis pain, menstrual cramps, and the common cold
Common side effects
- Gastrointestinal upset (nausea, dyspepsia, abdominal pain)
- Heartburn
- Dizziness
- Headache
- Rash
- Gastrointestinal bleeding (serious, rare)
Key clinical trials
- Naproxen Sodium/Acetaminophen Proof of Concept Dosing Study (PHASE2)
- Efficacy and Safety Study of a Test Naproxen Sodium 220mg Tablet in Postoperative Dental Pain (PHASE3)
- Bioequivalence of Single Dose Extended Release Naproxen Sodium (660 mg) Tablet Versus Naproxen Sodium (220 mg) Tablet Three Times Daily (PHASE1)
- Naproxen Sodium ER Pharmacokinetic Study (PHASE1)
- Single/Multiple Dose Bioavailability Trial (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: